Sugarloaf Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-72
Closed -$2.18K – 695
2023
Q1
$2.18K Hold
72
– – ﹤0.01% 611
2022
Q4
$2.04K Sell
72
-1
-1% -$32 ﹤0.01% 673
2022
Q3
$3K Sell
73
-60
-45% -$2.2K ﹤0.01% 661
2022
Q2
$4K Hold
133
– – ﹤0.01% 622
2022
Q1
$6K Buy
133
+61
+85% +$2.91K ﹤0.01% 541
2021
Q4
$4K Hold
72
– – ﹤0.01% 607
2021
Q3
$5K Sell
72
-250
-78% -$21K ﹤0.01% 600
2021
Q2
$30K Sell
322
-390
-55% -$33.2K 0.01% 352
2021
Q1
$54K Buy
+712
New +$70.6K 0.02% 259

Other funds holding ARKG

Sugarloaf Wealth Management's ARKG Position: Q2 2023 in Review

Sugarloaf Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2023, closing a stake of 72 shares — an estimated $2.18K sold.

Sugarloaf Wealth Management first reported a position in ARKG in Q1 2021 and held it in 9 quarters. The position peaked at $54K in Q1 2021. 292 funds tracked by Wall St. Rank hold ARKG as of Q2 2023.

  • Sugarloaf Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q2 2023 after selling out during the quarter.
  • Sugarloaf Wealth Management sold 72 ARK Genomic Revolution ETF shares in Q2 2023, an estimated $2.18K.
  • Sugarloaf Wealth Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 9 quarters.
  • Sugarloaf Wealth Management's ARK Genomic Revolution ETF position peaked at $54K in Q1 2021.
  • 292 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2023.

Based on Sugarloaf Wealth Management's 13F filing for Q2 2023, filed 13 Jul 2023.